PMID: 17323127

Robey RW, Polgar O, Deeken J, To KW, Bates SE
ABCG2: determining its relevance in clinical drug resistance.
Cancer Metastasis Rev. 2007 Mar;26(1):39-57., [PubMed]
Sentences
No. Mutations Sentence Comment
138 ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 17323127:138:18
status: VERIFIED
view ABCG2 p.Gln141Lys details
 Expression of the Q141K SNP in cell lines has been shown to lead to significantly lower IC50 values for ABCG2 substrates, including mitoxantrone, irinotecan, and SN-38 [119, 122]. Login to comment 139 ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 17323127:139:4
status: VERIFIED
view ABCG2 p.Gln141Lys details
 The Q141K SNP has been shown to influence the pharmacokinetics of orally administered drugs, including topotecan [125], diflomotecan [126] and 9-aminocamptothecin [127]. Login to comment 140 ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 17323127:140:59
status: VERIFIED
view ABCG2 p.Gln141Lys details
 As noted earlier, the higher plasma drug levels due to the Q141K SNP may result in exquisite sensitivity to certain orally administered chemotherapy drugs. Login to comment